Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
FA Moreira, M Grieb, B Lutz - … practice & research Clinical endocrinology & …, 2009 - Elsevier
Both agonists (eg Δ9-tetrahydrocannabinol, nabilone) and antagonists (eg rimonabant,
taranabant) of the cannabinoid type-1 (CB1) receptor have been explored as therapeutic
agents in diverse fields of medicine such as pain management and obesity with associated
metabolic dysregulation, respectively. CB1 receptors are widely distributed in the central
nervous system and are involved in the modulation of emotion, stress and habituation
responses, behaviours that are thought to be dysregulated in human psychiatric disorders …
taranabant) of the cannabinoid type-1 (CB1) receptor have been explored as therapeutic
agents in diverse fields of medicine such as pain management and obesity with associated
metabolic dysregulation, respectively. CB1 receptors are widely distributed in the central
nervous system and are involved in the modulation of emotion, stress and habituation
responses, behaviours that are thought to be dysregulated in human psychiatric disorders …